Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

Registrieren

GOSS Gossamer Bio Inc

0,7382

0,0054 (0,74%)

Zuletzt aktualisiert: 21:29:56

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Gossamer Bio Charts.

Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Gossamer Bio Charts.

News Gossamer Bio Inc

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Dienstag 14 Mai 2024 (24 Stunden vor) • Business Wire

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Freitag 10 Mai 2024 (5 Tage vor) • Business Wire

Form 8-K - Current report
Dienstag 7 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Dienstag 7 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
Dienstag 7 Mai 2024 (1 Woche vor) • Business Wire

Form 8-K - Current report
Montag 6 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Montag 6 Mai 2024 (1 Woche vor) • Business Wire

Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
Freitag 3 Mai 2024 (2 Wochen vor) • Business Wire

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
Dienstag 12 März 2024 (2 Monate vor) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Gossamer Bio Inc News-Artikel

Lockheed Martin

Societe Generale Effekten

LOPES BRASIL ON

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen